Abstract

OBJECTIVE. The purpose of this study is to evaluate high-resolution CT (HRCT) combined with PET/CT for preoperative differentiation of invasive adenocarcinoma (IAC) from preinvasive lesions and minimally invasive adenocarcinoma (MIA) (the combination of which is hereafter referred to as preinvasive-MIA) in lung adenocarcinoma manifesting as ground-glass opacity nodules (GGNs) 3 cm or smaller. MATERIALS AND METHODS. We retrospectively analyzed the data of patients with lung adenocarcinoma with GGNs that were 3 cm or smaller between November 2011 and November 2018. The HRCT and PET/CT parameters for GGNs were compared to differentiate between IAC and preinvasive-MIA. Qualitative and quantitative parameters were analyzed using univariate and multivariate logistic regression models. The diagnostic performance of different parameters was compared using ROC curves and the McNemar test. RESULTS. The study enrolled 89 patients (24 men and 65 women) with lung adenocarcinoma who had a mean (± SD) age of 60.1 ± 8.1 years (range, 36-78 years). The proportions of mixed GGN type, polygonal or irregular shape, lobulated or spiculated edge, and dilated, distorted, or cutoff bronchial sign were higher for IAC GGNs than for preinvasive-MIA GGNs, and the attenuation value of the ground-glass opacity component on CT (CTGGO), maximum standardized uptake value, and the standardized uptake value (SUV) index (i.e., the ratio of the tumor maximum SUV to the liver mean SUV) for IAC GGNs were also higher (p = 0.001-0.022). Logistic regression analyses showed that the CTGGO and SUV index were independent predictors for IAC GGNs. The accuracy of CTGGO in combination with the SUV index for predicting IAC was 81.4% on a per-GGN basis and 85.4% on a per-patient basis. The combined HRCT and PET/CT modality had higher sensitivity and accuracy than did morphologic features, HRCT, and PET/CT measurement parameters alone (p < 0.001). CONCLUSION. The combined HRCT and PET/CT modality is an effective method to preoperatively identify IAC in lung adenocarcinoma manifesting as GGNs 3 cm or smaller.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.